Israel Englander Greenwich Life Sciences, Inc. Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.31 - $20.32 $434,613 - $1.06 Million	52,300 Added 454.35%	63,811 $1.27 Million
Q4 2023 Feb 14, 2024	SELL	$7.77 - $12.3 $185,213 - $293,195	-23,837 Reduced 67.44%	11,511 $121,000
Q2 2023 Aug 14, 2023	SELL	$9.58 - $13.2 $330,088 - $454,819	-34,456 Reduced 49.36%	35,348 $340,000
Q1 2023 May 15, 2023	BUY	$12.12 - $20.8 $413,061 - $708,884	34,081 Added 95.4%	69,804 $963,000
Q4 2022 Feb 14, 2023	SELL	$9.04 - $16.88 $217,773 - $406,639	-24,090 Reduced 40.28%	35,723 $543,000
Q3 2022 Nov 14, 2022	SELL	$7.81 - $12.02 $238,040 - $366,357	-30,479 Reduced 33.76%	59,813 $544,000

1.01M

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $173M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.